Meeting
2013 ASCO Annual Meeting
Nuclear SMAD4 as a predictor of survival in patientes with extremity soft tissue sarcomas submitted to neoadjuvant chemotherapy.
Authors
Isabela Werneck Cunha
Pathology Department, Hospital A. C. Camargo, Sao Paulo, Brazil
Isabela Werneck Cunha , Ranyell Spencer Sobreira Batista , Paulo Roberto Stevanato , Samuel Aguiar Jr., Ademar Lopes , Celso Abdon Mello , Wilson Luiz da Costa Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 31, 2013 (suppl; abstr 10586)
DOI
10.1200/jco.2013.31.15_suppl.10586
Abstract #
10586
Poster Bd #
49D
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The impact of multimodality therapies in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program (TSP) experience.
First Author: Olga Vornicova
Poster
2020 ASCO Virtual Scientific Program
A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.
First Author: Michael B. Livingston
Poster
2018 ASCO Annual Meeting
Management and outcome of patients with neo-adjuvant chemotherapy (CT) in locally advanced soft-tissue sarcoma (LASTS): The Gustave Roussy experience.
First Author: Sarah Naomie Dumont
Poster
2017 ASCO Annual Meeting
Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas.
First Author: Frederick C. Eilber